International Renal Research Institute of Vicenza (IRRIV), Vicenza, Italy.
Department of Nephrology, San Bortolo Hospital, Vicenza, Italy.
Cardiorenal Med. 2023;13(1):46-55. doi: 10.1159/000529613. Epub 2023 Feb 14.
Fluid overload has been associated with untoward outcomes in a variety of clinical settings. Isolated extracorporeal ultrafiltration (UF) allows for mechanical extraction of excess fluid and optimization of volume status without the established risks associated with use of high-dose diuretics. Conventional machines for renal replacement therapy can be used to perform isolated UF. However, they typically need high blood flow rates with high circuit volumes and the therapy has to be performed by trained nurses. Herein, we describe a novel device, the Artificial Diuresis-1, or AD 1 (Medica S.p.A., Medolla, Italy), which is a portable technology designed to perform extracorporeal UF at bedside.
The AD 1 uses a polysulfone mini-filter to generate ultrafiltrate with the help of two forces: blood flow (Qb) and gravity (based on the height at which the ultrafiltrate collection bag is placed). In vitro experiments were performed using human blood to evaluate vascular access pressures and ultrafiltrate volumes using various central venous catheters (CVCs; 12 Fr bilume, 10 Fr with 2 separate lumens, pediatric catheter 7 Fr). A variety of combinations were tested with Qb of 20, 35, 50 mL/min and collection bag height at 20, 40, 60 cm, measuring the UF rate per minute while monitoring the pressures in the venous and arterial lines and filtration fraction.
The device's performance was as expected. Regarding the pediatric CVC, it was possible to perform measurements only with a Qb of 20 mL/min due to increased venous pressure. UF rates when lines were directly connected to the blood container as well as for CVC Tesio ranged from 3.7 to 11 mL/min, for the CVC Niagara™ from 4.5 to 12.5 mL/min, and for the CVC 7 Fr from 8.5 to 10 mL/min. The pressures of the vascular accesses were kept within a range of -5/-40 mm Hg for the artery and +10/+70 mm Hg for the vein. The highest venous pressure values were found with the CVC 7 Fr (+80/+100 mm Hg).
This novel device allows to treat patients with fluid overload in a variety of settings, from low-intensity department such as long-term care facilities to the intensive care unit. The device is small and portable, has a simple design, and is user friendly. Future studies will be needed to evaluate whether gentle UF and treatment of volume overload will translate into improvement in clinical outcomes such as a reduction in congestion-related hospital admissions.
在各种临床环境中,液体超负荷与不良结果有关。单独的体外超滤(UF)允许机械提取过多的液体,并优化容量状态,而不会产生与使用高剂量利尿剂相关的既定风险。用于肾脏替代治疗的常规机器可用于进行单独的 UF。然而,它们通常需要高血流量和高回路体积,并且治疗必须由经过培训的护士进行。在此,我们描述了一种新型设备,即人工利尿-1(AD1)(Medica S.p.A.,意大利梅多拉),这是一种便携式技术,旨在床边进行体外 UF。
AD1 使用聚砜 mini 过滤器在两种力的帮助下生成超滤液:血流(Qb)和重力(基于超滤液收集袋放置的高度)。使用人体血液进行体外实验,使用各种中心静脉导管(CVC;12Fr 双腔管、10Fr 带 2 个独立腔、儿科导管 7Fr)评估血管通路压力和超滤液体积。使用 Qb 为 20、35、50mL/min 和收集袋高度为 20、40、60cm 测试了各种组合,每分钟测量 UF 率,同时监测静脉和动脉线中的压力和过滤分数。
该设备的性能符合预期。对于儿科 CVC,由于静脉压增加,只能以 20mL/min 的 Qb 进行测量。当管路直接连接到血液容器以及 Tesio CVC 时,UF 率为 3.7 至 11mL/min,Niagara™ CVC 为 4.5 至 12.5mL/min,7Fr CVC 为 8.5 至 10mL/min。血管通路的压力保持在动脉为-5/-40mmHg,静脉为+10/+70mmHg 的范围内。7Fr CVC 的静脉压最高,为+80/+100mmHg。
这种新型设备允许在各种环境中治疗液体超负荷患者,从低强度的护理设施(如长期护理机构)到重症监护病房。该设备体积小,便于携带,设计简单,使用方便。需要进一步的研究来评估温和 UF 和容量超负荷治疗是否会转化为临床结果的改善,例如减少与充血相关的住院治疗。